A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladder for three months - ND

BOEHRINGER ING.0 个研究点目标入组 250 人开始时间: 2008年1月11日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 250

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•-Signed and dated written informed consent by the parent or guardian and, where appropriate, informed assent by the child, prior to admission into the study in accordance with GCP and the local legislation, has been obtained. -Patients of either sex; ages 2?16 years inclusive, with a body weight of 12.5 kg to a maximum of 100 kg. -Patients with a neuropathic bladder secondary to a known neurologic deficit (e.g., spina bifida). This includes children who are performing clean intermittent catheterization (CIC). -Patients with an elevated detrusor leak point pressures (LPP >=40 cm H2O) associated with a known neurological deficit and confirmed by two measurements on the same day, within 3 months prior to Visit 1.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Clinically significant abnormalities found at, or before randomization [i.e., abnormal vital signs (e.g., hypotension), abnormal ECG], as well as clinically significant findings during the physical examination, as determined by the investigator. -Clinically significant conditions which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patient?s ability to participate in the study. These conditions include, but are not limited to, the following: gastrointestinal, cardiovascular, hepatic, renal, hematologic, metabolic (including uncontrolled diabetes mellitus), immunological, hormonal disorders, respiratory disease, or cancer. -A history of relevant orthostatic hypotension, fainting spells or blackouts. Postural symptoms occurring (e.g., light-headedness, dizziness, and fainting) with or without a change in blood pressure and/or pulse rate within 6 weeks of Visit 1. -Patients with clinically significant laboratory abnormalities (based on investigator judgment) or laboratory values greater than 2x times the upper limit of normal range. -Severe hydronephrosis greater than Grade 3 (defined in Section 5.1.2). A renal ultrasound performed within 3 months prior to entering the study will be accepted as a baseline measurement if this assessment was performed while the patient was on a stable medication. -Patients who have a history of bladder neck surgery, bladder augmentation or permanently exteriorized bladder drainage procedures and those patients who have had any surgical procedure under general anesthesia within 30 days prior to Visit 2. -Patients with a significant psychiatric disorder that prevents their comprehension of consent and their ability to comply with the protocol. -Patients on drug therapy, or non-drug therapy including electro-stimulation for their neuropathic bladder initiated during the four weeks prior to screening or anticipated. -Patients taking warfarin, ranitidine or cimetidine. -Patients who have a history of allergy/hypersensitivity (including drug and sulfa allergy) which is deemed relevant to the trial as judged by the investigator. -Use of alpha-blockers (e.g., prazosin, terazosin, alfuzosin, doxazosin, tamsulosin) within 30 days of screening visit. -Patients having a symptomatic urinary tract infection at screening. After the UTI has been treated and stabilized (no longer symptomatic) the patient may be entered into the study. -Patients participating in another trial with an investigational drug within 1 month prior to screening or during the trial. -Patients with a positive pregnancy test or a patient that is lactating. All female patients of child bearing potential, who are sexually active in the opinion of the investigator, must be using two accepted means of birth control. -Patients or their parents or guardians who, in the investigator?s opinion cannot understand the terms of the informed consent form and/or subject information.

研究者

发起方

BOEHRINGER ING.

相似试验

进行中（未招募）

不适用

A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladder for three monthseurogenic BladderMedDRA version: 8.1Level: LLTClassification code 10029279Term: Neurogenic bladder

EUCTR2006-003048-52-DEBoehringer Ingelheim Pharma GmbH & Co. KG120

进行中（未招募）

不适用

EUCTR2006-003048-52-BESCS Boehringer Ingelheim Comm.V120

进行中（未招募）

2 期

Study to determine the effectiveness and safety of DNL310 vs idursulfase in pediatric participants with neuronopathic or non-neuronopathic Hunter Syndrome

ISRCTN11652897Denali Therapeutics (United States)54

进行中（未招募）

不适用

A phase II, multicentre,randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patientsEnsayo clínico de fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y búsqueda de dosis para investigar la eficacia y la seguridad de 10 y 20 mg/día de Ciclosporina A Liposómica aerosolizada (L-CsA) frente a placebo aerosolizado en la prevención del síndrome de bronquiolitis obliterante (SBO) en pacientes con trasplante pulmonar

EUCTR2008-003800-73-ESPari Pharma GmbH134

进行中（未招募）

不适用

EUCTR2008-003800-73-DKPari Pharma GmbH134